ストックスクリーナーアプリを入手
6.28
3.97%
0.24
アフターアワーズ：
6.28
前日終値:
$6.04
開ける：
$5.91
24時間の取引高:
591.62K
Relative Volume:
1.40
時価総額：
$207.73M
収益：
-
当期純損益:
$-62.31M
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-8.72%
1か月 パフォーマンス:
+2.61%
6か月 パフォーマンス:
-59.95%
1年 パフォーマンス:
-54.79%
1日の値動き範囲:
$5.81
$6.34
1週間の範囲:
$5.81
$7.40
52週間の値動き範囲:
$5.77
$22.33
Lexeo Therapeutics Inc Stock (LXEO) Company Profile
名前
Lexeo Therapeutics Inc
セクター
電話
(212) 547-9879
住所
345 PARK AVENUE SOUTH, NEW YORK
LXEO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LXEO
Lexeo Therapeutics Inc
|
6.28 | 207.73M | 0 | -62.31M | 0 | -2.4445 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Lexeo Therapeutics Inc Stock (LXEO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-06-13 | 開始されました | Robert W. Baird | Outperform |
| 2024-06-06 | 開始されました | H.C. Wainwright | Buy |
| 2023-11-28 | 開始されました | Chardan Capital Markets | Buy |
| 2023-11-28 | 開始されました | JP Morgan | Overweight |
| 2023-11-28 | 開始されました | Leerink Partners | Outperform |
| 2023-11-28 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-11-28 | 開始されました | Stifel | Buy |
すべてを表示
Lexeo Therapeutics Inc (LXEO) 最新ニュース
BNP Paribas Financial Markets Increases Stake in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
When (LXEO) Moves Investors should Listen - Stock Traders Daily
Charles Schwab Investment Management Inc. Buys 33,013 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Lexeo Therapeutics appoints new CFO amid growth - Investing.com
Lexeo Therapeutics Appoints Dr. Kyle Rasbach as CFO - TipRanks
Lexeo Therapeutics Names Kyle Rasbach Chief Financial Officer - MarketWatch
Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer - The Manila Times
Lexeo Therapeutics, Inc. Appoints Kyle Rasbach as Chief Financial Officer - Marketscreener.com
Lexeo Therapeutics' SWOT analysis: gene therapy stock's potential and pitfalls - Investing.com
Lexeo Therapeutics' SWOT analysis: gene therapy stock poised for catalysts By Investing.com - Investing.com Nigeria
Lexeo Therapeutics' SWOT analysis: gene therapy stock poised for catalysts - Investing.com India
Frazier Life Sciences Management L.P. Invests $11.31 Million in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - MarketBeat
Point72 Asset Management L.P. Makes New $3.35 Million Investment in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - MarketBeat
Janus Henderson Group PLC Purchases 599,203 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - MarketBeat
RA Capital Management L.P. Reduces Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - MarketBeat
LXEOLexeo Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Verition Fund Management LLC Boosts Stake in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - MarketBeat
Eventide Asset Management LLC Has $16.78 Million Holdings in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - MarketBeat
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Shares Sold by Braidwell LP - MarketBeat
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Insider Spends US$105k Buying More Shares In Lexeo Therapeutics - Simply Wall St
Paula H. Cholmondeley Bought 96% More Shares In Lexeo Therapeutics - Yahoo Finance
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Rating of "Buy" from Analysts - MarketBeat
Insider Buying: Paula Cholmondeley Acquires 15,000 Shares of Lex - GuruFocus.com
Can Lexeo's HEROIC-PKP2 Data Reignite Stock Rally? - RTTNews
Lexeo stock hits 52-week low at $5.8 amid market challenges - Investing.com India
Here's Why We're Watching Lexeo Therapeutics' (NASDAQ:LXEO) Cash Burn Situation - Yahoo Finance
(LXEO) Trading Advice - Stock Traders Daily
Lexeo Therapeutics (NASDAQ:LXEO) Stock Price Expected to Rise, HC Wainwright Analyst Says - Defense World
FY2024 EPS Forecast for Lexeo Therapeutics Cut by Analyst - MarketBeat
FY2024 Earnings Estimate for LXEO Issued By Leerink Partnrs - MarketBeat
HC Wainwright Has Negative Estimate for LXEO FY2024 Earnings - MarketBeat
Lexeo Therapeutics (NASDAQ:LXEO) Stock Price Expected to Rise, Chardan Capital Analyst Says - Defense World
Lexeo Therapeutics Advances Cardiac Portfolio Amid Financial Report - TipRanks
Janus Henderson Group PLC's Strategic Acquisition in Lexeo Thera - GuruFocus.com
Eventide Asset Management's Strategic Reduction in Lexeo Therape - GuruFocus.com
Lexeo Therapeutics, Inc. Appoints Tolga Tanguler to Its Board of Directors - Marketscreener.com
Lexeo Therapeutics Strengthens Leadership with New Board Appointment - TipRanks
Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results - The Manila Times
Lexeo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Lexeo Therapeutics Secures FDA Alignment, Reports $157M Cash Position Despite Q3 Loss | LXEO Stock News - StockTitan
Lexeo stock hits 52-week low at $7.54 amid market challenges By Investing.com - Investing.com South Africa
Lexeo stock hits 52-week low at $7.54 amid market challenges - Investing.com India
Lexeo Therapeutics' Gene Therapy LX1001 Increases APOE2 Expression in Patients With Alzheimer Disease - CGTLive™
Analysts Set Lexeo Therapeutics, Inc. (NASDAQ:LXEO) PT at $22.14 - MarketBeat
Lexeo Therapeutics (NASDAQ:LXEO) Earns Buy Rating from HC Wainwright - MarketBeat
Lexeo shares dip on early data with Alzheimer's gene therapy - pharmaphorum
Lexeo reports positive Alzheimer's drug trial results - Investing.com India
Lexeo reports positive Alzheimer's drug trial results By Investing.com - Investing.com South Africa
Lexeo Therapeutics Announces Positive Interim Data for - GlobeNewswire
How now, tau? ‘Newer science’ shines in Lexeo Alzheimer’s data - BioWorld Online
Lexeo Therapeutics Inc (LXEO) 財務データ
収益
当期純利益
現金流量
EPS
Lexeo Therapeutics Inc (LXEO) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Townsend Richard Nolan | Chief Executive Officer |
Dec 10 '24 |
Sale |
8.20 |
2,500 |
20,491 |
120,695 |
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):